Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the “Company” or “Lexaria”) announces that, on January 29, it submitted its much-anticipated Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for its planned U.S. phase 1b hypertension clinical trial HYPER-H23-1 of DehydraTECH-CBD.
January 30, 2024
· 5 min read